What Is The 5-year Survival Rate For Patients Who Undergo Curative He

1.	What Is The 5-year Survival Rate For Patients Who Undergo Curative Hepatic Resection Of Colorectal Liver Metastases?
Answer» In patients with unresectable METASTATIC colorectal cancer, modern systemic chemotherapy REGIMENS provide median survival times RANGING from 12 to 24 months, and survival beyond 5 years is uncommon. In contrast, historical 5-year survival rates for patients undergoing hepatic resection with curative intent range from 30% to 40%, with several more recent SERIES reporting rates APPROACHING 60%. In patients with unresectable metastatic colorectal cancer, modern systemic chemotherapy regimens provide median survival times ranging from 12 to 24 months, and survival beyond 5 years is uncommon. In contrast, historical 5-year survival rates for patients undergoing hepatic resection with curative intent range from 30% to 40%, with several more recent series reporting rates approaching 60%.

What Is The 5-year Survival Rate For Patients Who Undergo Curative Hepatic Resection Of Colorectal Liver Metastases?

Answer»

In patients with unresectable METASTATIC colorectal cancer, modern systemic chemotherapy REGIMENS provide median survival times RANGING from 12 to 24 months, and survival beyond 5 years is uncommon. In contrast, historical 5-year survival rates for patients undergoing hepatic resection with curative intent range from 30% to 40%, with several more recent SERIES reporting rates APPROACHING 60%.

In patients with unresectable metastatic colorectal cancer, modern systemic chemotherapy regimens provide median survival times ranging from 12 to 24 months, and survival beyond 5 years is uncommon. In contrast, historical 5-year survival rates for patients undergoing hepatic resection with curative intent range from 30% to 40%, with several more recent series reporting rates approaching 60%.

Discussion

No Comment Found

Related InterviewSolutions

What Is The 5-year Survival Rate For Patients Who Undergo Curative Hepatic Resection Of Colorectal Liver Metastases?
The Immunomodulating Monoclonal Antibody Alemtuzumab Is Associated With Which Infectious Complication?
Is Cytoreductive Nephrectomy Recommended For Patients With Metastatic Renal Cell Carcinoma (rcc) Before Cytokine Or Targeted Therapy?
Which Of The Following Statements Concerning The American Cancer Society Nutrition And Exercise Guidelines For Cancer Survivors Is False?
The Annual Risk For Endometrial Cancer In Post-breast Cancer Patients After 5 Years Of Adjunctive Therapy With Tamoxifen Is 2 Cases Per_________?
Rituximab In Combination With Chop (r-chop) Was Approved In 2006 By The Fda For Treatment Of Diffuse Large B-cell Lymphoma (dlbcl). The Addition Of Rituximab To Standard Chemotherapy Has Been Shown To Benefit Which Patient Population?
What Is The Main Cause Of Hepatocellular Carcinoma (hcc) In The United States?
A 53-year-old White Man With No Family History Of Colorectal Cancer Had His First Screening Colonoscopy. He Was Found To Have A < 1 Cm Tubular Adenoma With Low-grade Dysplasia. When Should He Schedule His Next Colonoscopy?
What Is A Possible Intervention To Treat Breathlessness In End-stage Cancer Patients?
Risk Factors For Anthracycline-induced Cardiomyopathy Include?